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ABSTRACT 
Since their discovery in the early 1990s, peroxisome proliferator-activated receptors (PPARs) 
have become an extremely important set of targets for drug discovery. The ligand-induced 
transcription factors that regulate the transcription of target genes in response to specific 
ligands, keeps on broadening its repertoire as new knowledge are uncovered. PPARs are 
nuclear lipid-activated receptors that control a vast variety of genes in several pathways of 
lipid metabolism. This includes fatty acid transport, uptake by the cells, intracellular binding 
and activation, as well as catabolism (β-oxidation and ω-oxidation) or storage. They are 
important pharmacological targets of treatment of obesity, diabetes and lipid disorders. 
 
Although, PPARs are among the most studied nuclear receptors, there is little knowledge of 
their activity and functions in fish. Atlantic salmon- Salmo salar L. belongs to the family 
Salmonidae (Salmonids) and the order Salmoniformes. Norway have traditionally been 
farming Atlantic salmon since the early 1970s, and is today one of the major producers of 
farmed salmon for human consumption. The quality of fish depends much on the mechanisms 
that keep the fish healthy. The adipose regulations in fish are still unknown, and it is of great 
interest that they are investigated. 
 
One of the goals of this thesis was to study PPAR gene expression in Atlantic salmon. We 
compared PPAR tissue distribution in various fish tissue and cell lines. The tissue distribution 
of PPARs in salmon was comparable to what has been described for mammals, a higher 
concentration in tissues where adipose metabolism is more relevant. We also exposed SHK-1 
and ASK cells (Atlantic salmon head kidney cells) to PPAR agonist treatment and found that 
when activating PPARγ, an up-regulation of target genes like SR-BI and CD 36 where seen. 
These target genes play a key role in regulation of cholesterol homeostasis and have 
previously been shown to be up-regulated by PPARγ in mammals. To further investigate 
PPARγ, we performed transfection studies. Although, we obtained low transfection 
efficiency, the findings showed same trend in PPAR transcription activity regulation.  
 
Highly specific antibodies against fish antigens are rare. We therefore performed assays to 
test a novel anti salmon-PPARγ antibody for specificity, applying methods such as 
immunostaining and western blotting. If the PPARγ antibody proved specific, it would 
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provide us with an important tool in PPAR studies. Unfortunately this was not the case in our 
study. 
 
Our results of PPAR activity in Atlantic salmon head kidney cells agreed in many aspects 
with previous findings in mammalian cells. However, there were low effects of ligand 
treatment, and it came apparent during this work that PPAR agonists could have toxic effects 
on SHK-1 and ASK cells in the concentrations employed here.  
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ABBREVIATIONS 
 
 
ACO      Acyl-Coenzym A oxidase 
AF-1     Activation function-1 
AF-2     Activation function-2 
APS    Ammonium persulphate 
ASK     Atlantic salmon head kidney cell 
 
BSA     Bovine serum albumine 
 
CD 36    Scavenger receptor subclass B member 
CE     Cholesteryl esters 
cDNA     complementary DNA 
 
DBD     DNA-binding domain 
DMSO    Dimethyl sulfoxide 
DR     Direct repeats 
 
EF1-α     Elongation factor 1-α 
ER     Everted repeats 
 
FA    Fatty acid 
FBS     Foetal Bovine Serum 
FCS     Foetal Calf serum 
 
GFP     Green fluorescence protein 
 
HDL     High density lipoprotein 
HRP     Horse reddish protein 
 
IR     Inverted repeats 
 
LBD     Ligand-binding domain 
LDL     Low density lipoprotein 
LPL     Lipoprotein lipase 
LXR     Liver X receptor 
 
MeOH    Methanol 
mRNA    Messenger RNA 
 
(n)     nucleotid 
NR     Nuclear receptor 
 
PBS     Phosphate Buffered Saline 
PBS-T    PBS+ Tween 20 
PFA     Paraformaldehyde 
 
PPAR     Peroxisome proliferator-activated receptor 
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PPAR-β    Peroxisome proliferator-activated receptor-beta 
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SR-BI     Scavenger receptor class B type I 
 
TEMED   (N,N,N,N,-tetramethyl-Ethylendiamin) 
TF     Transcription factor 
TNF-α    Tumor necrosis factor-α 
TTA     Tetradecylthioacetic acid 
TZD     Thiazolidinediones 
 
UV     Ultra violet 
 
2-ME     β-mercaptoethanol 
Δ-5     Delta five fatty acid desaturase  
Δ-6     Delta six fatty acid desaturase  
18S      18S ribosomal RNA 
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1 GENERAL INTRODUCTION 
 
1.1 Transcriptional regulation 
There are numerous factors involved in the transcription of genes that control the metabolism 
in any organism. In the human genome, these transcription factors (TFs) make up for 
approximately 10 percent of all known protein coding genes. This relatively large number of 
TFs indicates a complex and tight regulation of metabolic control (Lander, Linton et al. 2001). 
The expression of genes is dependent on the TFs binding to specific DNA sites called 
response elements (RE), in the promoter (regulatory) area of the target genes (Lee and Young 
2000). The promoter is localized in front of the coding sequence of a gene which consists of a 
transcription initiation site, often a TATA box and / or an initiator element that facilitate the 
assembly of the general transcription factors that are required for specific promoter binding by 
RNA polymerase II (Lee and Young 2000; Levine and Tjian 2003; Smale and Kadonaga 
2003). 
 
1.2 Nuclear receptors 
Nuclear receptors are a superfamily of DNA-binding transcription factors that are similar in 
structure, and believed to have evolved from a common ancestor. The nuclear receptors 
regulate the expression of target genes that have effect on processes like reproduction, 
development and general metabolism. The nuclear receptor superfamily includes the classic 
endocrine receptors that mediate the actions of steroid hormones, thyroid hormones, and the 
fat-soluble vitamins A and D, as well as a large number of so-called orphan nuclear receptors. 
The latter group is divided in two subgroups; the adopted orphan receptors, which have 
known ligands, and the orphan receptors where the ligands are still unknown. Members of the 
adopted orphan receptor group are also referred to as “sensor” receptors (Desvergne, Michalik 
et al. 2006), which include for example, receptors for fatty acids, liver X receptor (LXR) and 
retinoid X receptor (RXR) (figure 1.1) (Evans 1988).  
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Figure 1.1 The nuclear receptor superfamily. The classic hormone receptors bind with high affinity to 
molecules. Their activation is associated with many metabolic adjustments; they are key factors of endocrine 
homeostasis. The “sensor” receptors are sensors of the metabolic status, they respond both to exogenous signals 
as well as metabolites generated in the organism, and are responsible for the metabolic adaptation at on cellular, 
organ, and whole organism level. The orphan receptors display the structural characteristics of nuclear receptors 
including a ligand binding domain. Thus, no ligand has so far been identified for these receptors (Desvergne, 
Michalik et al. 2006). 
 
1.2.1 Nuclear receptor structure 
Nuclear receptors have a ligand-independent transcription activation domain at the NH2 –
terminal, that is called A/B domain. Since this region is important for transcription activation, 
it is often referred to as the activation function-1 (AF-1) (Lees, Fawell et al. 1989; Tora, 
White et al. 1989). A DNA-binding domain (DBD or C domain) is found in the core of 
nuclear receptor (NR) containing two highly conserved ‘zinc-finger’ domains that target the 
receptor to specific DNA response element (RE). The D domain is a variable hinge region 
that gives the receptor flexibility and allows simultaneous receptor dimerization and DNA 
binding. Adjacent to the hinge region is the ligand-binding domain (LBD or E/F domain) that 
mediates ligand binding, dimerization, interaction with heat shock proteins, nuclear 
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localization and transactivation. Located at the COOH-terminal is the activation function-2 
(AF-2) domain  that binds co-regulators (Chawla, Repa et al. 2001). The nuclear receptors 
bind to REs at their respective target genes that consist of one or two consensus core half site 
sequences in the promoter region. Binding occurs either as a monomer, homodimer or a 
heterodimeric complex with another NR; often with RXR (receptor for 9-cis-retinoic acid) to 
the consensus sequence AGGTCA. The consensus sequences are arranged as direct-(DR), 
inverted- (IR) or everted (ER) repeats separated by 1-6 nucleotides (n). Ligand-binding 
induces conformational changes in the nuclear receptor molecule. This cause translocation to 
the nucleus and changes in transcriptional activity of target genes by increasing or decreasing 
receptor activity (figure 1.2) (Smirnov 2002).  
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Figure 1.2 Nuclear Receptors as Ligand-Dependent Transcription Factors.  (A) Shows the structure of the 
nuclear receptor, which includes N-terminal activation function 1 (AF-1), DNA binding, ligand binding, and C-
terminal AF-2 domains. Responsive elements in the nuclear receptor can be configured as either direct, inverted, 
or everted repeats of the hexad core sequence AGGTCA (B). The number of nucleotides between the two core 
elements (n) confers additional specificity. (C and D) RXR heterodimers constitutively bind to response 
elements in the promoter regions of target genes. In Panel C, in the absence of agonist ligand, the AF-2 domain 
conformation promotes receptor interaction with co-repressors. The multiple-subunit co-repressor complex 
stabilizes repressive local chromatin structure and blocks access of the transcription machinery (red X) to the 
promoter. In Panel D, ligands diffuse across the nuclear membrane and bind to receptor ligand-binding domains. 
Ligand binding triggers a conformational change in the AF-2 domain, which destabilizes co-repressor interaction 
and promotes co-activator binding. Multiple-subunit co-activator complexes activate local chromatin structure 
and recruit the transcription machinery to the promoter, where target-gene transcription commences (adapted 
from (Shulman and Mangelsdorf 2005). 
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1.3 Peroxisome proliferator-activated receptors (PPARs)  
Peroxisome proliferator-activated receptors are ligand-regulated transcription factors and 
belong to the nuclear receptor superfamily.  PPARs are some of the most examined nuclear 
receptor because of their involvement in regulation of lipid homeostasis (Desvergne and 
Wahli 1999). 
 
1.3.1 Structure and activity of PPARs 
Like the other members of the nuclear receptor superfamily, PPAR proteins are also 
composed of several different domains (figure 1.3).  
 
 
 
Figure 1.3. Structure of a PPAR molecule. (Blanquart, Barbier et al. 2003) 
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1.3.2 PPAR binding 
The transcription of PPAR is regulated by their specific target genes binding to a PPAR 
response element (PPRE) located in the regulatory area of the gene (figure 1.4). This DNA 
element is a DR1 which means that the RE consists of a direct repeat of the consensus 
sequence, AGGTCA half site spaced by one (or two) nucleotides (Marx, Duez et al. 2004). 
 
 
Figure 1.4 When PPAR is activated by ligands, PPAR heterodimerizes with RXR and regulate transcription by 
binding to a specific PPAR response element (PPRE) in the promoter in the target gene. 
 
A common feature among some of the NRs is that they transcriptionally 
regulate their target genes as heterodimers with retinoid X receptors (RXRs). The 
PPARs are activated by specific ligands which bind to their LBD. PPARs are activated by a 
variety of endogenous compounds such as fatty acids and eicosanoids, but more potent are the 
synthetic PPAR ligands; fibrates and thiazolidinediones (Berger and Moller 2002). The 
activation of PPARs depends greatly on their particular ligand binding properties, which have 
important consequences for the PPAR biology. For instance, PPARs accommodates several 
 14
types of ligand, the molecules that specifically bind to PPAR do so with various affinities and 
there is some overlap in ligand recognition by the different PPAR isotypes (some ligand binds 
to more than one isotype)(Desvergne and Wahli 1999). The PPARs are important 
pharmacological targets for treatment of obesity, diabetes and lipid disorders. 
 
1.4 PPAR isotype 
There are three isotypes of peroxisome proliferator-activated receptors, designated PPARα 
(NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3)(Issemann and Green 1990). Although all 
three isoforms share similar protein sequence and structure, they differ in tissue distribution, 
ligand selectivity and biological actions (figure 1.5) (Desvergne and Wahli 1999; Escher, 
Braissant et al. 2001).   
 
 
Figure 1.5 Metabolic integration by PPARs. The three PPAR isoforms regulate lipid and glucose homeostasis 
through coordinated activities in liver, muscle and adipose tissue. Adopted from (Evans, Barish et al. 2004) 
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1.4.1 PPARα 
PPARα is expressed in tissues with high β-oxidation activity corresponding to its 
role in regulating the oxidation of fatty acids, liver tissue, brown adipose tissue, muscle, heart 
and kidney tissues (Ristow, Muller-Wieland et al. 1998). During a prolonged fast (overnight 
or starvation) fatty acids are released from the adipose tissue and transported into the liver 
where PPARα is heavily induced. PPARα is irreplaceable for a proper response to fasting in 
liver. (Kersten, Seydoux et al. 1999). Activation of PPARα by fatty acids promotes hepatic 
fatty acids oxidation to generate ketone bodies and by this provide an energy source for 
peripheral tissues. The importance of this is seen in PPARα- null mice, as they are unable to 
meet the energy demands during fasting and consequently suffers from hypoglycaemia, 
hyperlipidemia, hypoketonemia and fatty liver (Kersten, Seydoux et al. 1999). The induction 
of fatty acids oxidation by PPARα activation improves plasma lipid profiles. PPARα selective 
agonists like fibrates are often used to treat hypertriglyceridemia, as it lower plasma 
triglycerides, reduce adiposity and improve hepatic and muscle steatosis, which consequently 
improve insulin sensitivity (Guerre-Millo, Gervois et al. 2000; Chou, Haluzik et al. 
2002).Other ligands are polyunsaturated fatty acids, including DHA and EPA, oxidised 
phospholipids and lipoprotein lipolytic products (Marx, Duez et al. 2004) 
 
1.4.2 PPARγ     
PPARγ is found in high concentrations in white adipose tissue and macrophages (Fajas, 
Auboeuf et al. 1997). The high expression of PPARγ in white adipose tissue is linked to its 
role as a crucial regulator of the adiopogenesis, the process of preadipocytes maturing into 
adipocytes(Tontonoz, Hu et al. 1994; Rosen, Walkey et al. 2000). This is supported by the 
findings that PPARγ knockout mice fail to develop adipose tissue (Barak, Nelson et al. 1999). 
PPARγ ligands are naturally occurring fatty acids derivatives, prostaglandin derivatives and 
synthetic compounds such as the antidiabetic thiazolidinediones (TZDs). When acting as 
direct agonists for PPARγ, these drugs reduce peripheral insulin resistance and thus lower 
blood glucose levels in patients with type 2 diabetes. The activation of PPARγ results in a 
reduced release of FAs and insulin resistance-mediating adiopocytokines, such as tumor 
necrosis factor- α (TNF-α), leptin or resistin, and an increased production of the antidiabetic 
adiponectin, which promotes fatty acid oxidation and insulin sensitivity in liver and muscle 
tissue (Berg, Combs et al. 2001; Yamauchi, Kamon et al. 2001; Marx, Duez et al. 2004). 
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1.4.3 PPARβ/δ 
PPARβ/δ has earlier received less attention than the other PPARs, mainly because of its 
ubiquitous expression and until recently unknown functions. It is activated by polyunsaturated 
FAs (PUFAs), prostaglandins and synthetic compounds. Similar to PPARα, PPAR β/δ it plays 
an important role in the regulation of glucose and lipid levels in plasma, by stimulating FA 
oxidation in heart and skeletal muscle. The synthetic PPARβ/δ agonist GW501516 has shown 
its ability to lower plasma triglyceride level in obese monkeys, while raising high-density 
lipoprotein levels (Oliver, Shenk et al. 2001). Studies conducted with GW501516, reveal 
PPARβ/δ as a powerful regulator of fatty acid catabolism and energi homeostasis (Peters, Lee 
et al. 2000; Barak, Liao et al. 2002). Activated receptors induces genes that are required for 
fatty acids catabolism and adaptive thermogenesis (Wang, Lee et al. 2003). Treatment with 
PPARβ/δ agonist significant retards weight gain in animals and it also improves insulin 
resistance induced by high-fat diet, probably as a consequence of increased fat burning by 
muscle and the overall improvement in systemic lipid metabolism (Luquet, Lopez-Soriano et 
al. 2003). 
 
1.5 PPAR ligands 
1.5.1 Fenofibrates 
Fenofibrates belongs to a class of hypolipidemic drugs, which are used in treatment of 
dyslipidemic patients. The fenofibrates act as peroxisome proliferator-activated receptor α 
(PPAR α) ligands, which are involved in the regulation of the expression of a number of 
genes which are critical for lipid and lipoprotein metabolism (figure 1.6) (Staels, 
Dallongeville et al. 1998). The known target genes of PPAR α include acyl-coenzym A 
oxidase (ACO), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, thiolase used for 
peroxisomal fatty acid β-oxidation, carnitine palmitoyltransferase I used for mitochondrial 
fatty acid β-oxidation, apolipoprotein C-III and lipoprotein lipase (LPL) used for the 
hydrolysis of plasma triglycerides (Auwerx, Schoonjans et al. 1996). 
To some extent, fenofibrates seem to regulate energy homeostasis. When there is an excessive 
energy intake, an increase in the concentrations of plasma triglycerides, cholesterol and lipids 
accumulation in adipose tissue is observed (Chaput, Saladin et al. 2000). Fenofibrates increase 
hepatic fatty acid oxidation and decrease hepatic triglycerides; this may inhibit an increase in 
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body weight, which suggests that PPARα may have a role in the regulation of obesity. Studies 
have shown that PPARα-deficient mice have abnormal triglyceride and cholesterol 
metabolism. These mice eventually become obese with increasing age (Costet, Legendre et al. 
1998) 
1.5.2  Rosiglitazone 
Rosiglitazone is a thiazolidinedione (TZD), also referred to as ‘glitazone’, that belongs to a 
class of antidiabetic drugs that improves insulin sensitivity. Rosiglitazone is an agonist and 
acts by activating peroxisome proliferator-activated receptor gamma (PPARγ). Activation of 
PPARγ alters the transcription of genes involved in glucose and lipid metabolism and the 
energy balance, including those that code for lipoprotein lipase (LPL), fatty acid transporter 
protein, adipocyte fatty acid binding protein and fatty acyl-CoA synthase. Rosiglitazone 
reduce insulin resistance in adipose tissue, muscle and liver. However, PPARγ is 
predominantly expressed in adipose tissue.(Hauner 2002). Rosiglitazone markedly influence 
lipid metabolism by decreasing plasma triglyceride, free fatty acid and LDL-cholesterol 
levels, and by increasing plasma HDL-cholesterol concentration. Even though rosiglitazone 
do not stimulate insulin secretion, it does improve the secretory response of beta cells to 
insulin (Komers and Vrana 1998). 
1.5.3 Tetradecylthioacetic acid (TTA) 
Tetradecylthioacetic acid (TTA) is a non-β-oxidizable fatty acid analogue, which regulates 
lipid homeostasis. TTA has been shown to both up-and down regulate a number of genes 
encoding for regulatory factors in lipid metabolism, most likely through the action of lipid-
activated transcription factors like PPARs (Hihi, Michalik et al. 2002). TTA activates all three 
isotype PPAR in the ranking order PPAR alpha > PPAR beta/delta > PPAR gamma. Studies 
shows that a TTA-induced increase in hepatic fatty acid oxidation, together with ketogenesis 
draining fatty acids from blood and extrahepatic tissues, may contributes to a beneficial effect 
on fat mass accumulation and peripheral insulin sensitivity (Madsen, Guerre-Millo et al. 
2002).  
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Figure 1.6 The PPAR signaling pathway and its natural and synthetic activators. Activation by its 
respective ligands, PPARs heterodimerize with the receptor for 9-cis-retinoic acid (9cRA), RXR, and bind to 
specific REs in the regulatory regions of target genes (Staels, Dallongeville et al. 1998). 
 
1.6 PPARs target genes 
1.6.1 Scavenger receptor class B type 1 (SR-B1) and CD 36 
SR-BI and CD 36 are both members of the scavenger receptor superfamily which contains a 
vast variety of transmembrane receptors different in structure, expression and function but 
with the common feature of binding modified LDL. The scavenger receptor superfamily is 
divided into six classes A-F (figure 1.7) (Greaves, Gough et al. 1998). 
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Figure 1.7 The scavenger receptor superfamily, classification and their proposed structure (Greaves, 
Gough et al. 1998). 
SR-BI is mainly expressed in tissues with critical roles in cholesterol metabolism, for instance 
the liver and steroidogenic tissues. SR-BI is a receptor for native and modified lipoproteins, 
and mediates the bidirectional exchange of lipids (Acton, Rigotti et al. 1996) SR-BI binds 
with high affinity, and facilitate both  the selective uptake of high density lipoprotein (HDL), 
cholesteryl ester (CE) and the efflux of cellular cholesterol to circulating HDL particles (Ji, 
Jian et al. 1997). SR-BI primary function is maintaining cholesterol homeostasis, in addition it 
has been shown that SR-BI can mediate phagocytosis of apoptotic cells through binding of 
phosphatidylserine residues on the cell surface (Rigotti, Acton et al. 1995). SR-BI expression 
level is controlled by hormones, fatty acids, lipoproteins and nutrients through a complex 
regulatory network of transcription factors (Rhainds and Brissette 2004). 
CD 36 is a surface glycoprotein which is expressed by monocyte/macrophages, platelets, 
microvascular endothelial cells, and adipose tissue (Nicholson, Frieda et al. 1995) CD 36 
recognizes a multitude of ligands, and is for instance a receptor for oxidized LDL, long-chain 
fatty acids and the membrane of cells undergoing apoptosis (Nicholson, Frieda et al. 1995). 
CD 36 seem to play a strategic role in the lipoprotein and lipid metabolism (Febbraio, 
Abumrad et al. 1999). The major role of CD 36 in fatty acid uptake and lipid metabolism is 
seen in CD 36-null mice that generate increased plasma levels of cholesterol, triacylglycerol 
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and fatty acids (Febbraio, Abumrad et al. 1999). Oxidised LDL stimulate its own uptake by 
induction of CD 36 gene expression, which must involve activation of transcription factor; 
PPARγ (Nicholson, Han et al. 2001). 
 
1.6.2 Acyl- Coenzym A oxidase (ACO) 
Peroxisomes are single membrane-bound cytoplasmic organelles that participate in a variety 
of metabolic processes. These organelles are present in virtually all eukaryotic cells and are 
most abundant in mammalian liver and kidney. The most extensively characterized process 
performed by peroxisomes is fatty acid β-oxidation, a cyclic pathway involved in the 
degradation of lipids (Wang, Le Dall et al. 1999). Via β-oxidation, peroxisomes play an 
essential role in both the metabolism of lipids and also in bile acid synthesis (Aoyama, 
Tsushima et al. 1994). ACO isozymes catalyze the first rate-limiting steps of the peroxisomal 
β-oxidation, This enzyme is critical for completion of straight chain fatty acid β-oxidation 
(Ngo, McKinnon et al. 2003). Induction of ACO occurs at a transcriptional level with the 
activation of PPARα (Reddy, Goel et al. 1986). 
 
1.6.3 Lipoprotein lipase (LPL) 
LPL is the extrahepatic enzyme that is responsible for the hydrolysis of triglycerides in 
plasma lipoproteins. After synthesis in parenchymal cells, LPL is secreted and travels the 
interstitial space before they bind to the luminal surface of the vascular endothelial cells. The 
amount of enzymatically active LPL in vivo varies greatly with feeding, fasting, and with a 
number of pharmacologic intervention (Saxena, Witte et al. 1989). LPL mediates the uptake 
of fatty acids and can to some extent control lipid storage between liver and extrahepatic 
tissues. LPL activity gives a strong peripheral accumulation of lipids (Griffin, Butterwith et 
al. 1987; Andre, Guy et al. 2007). 
1.6.4 Delta 5 (Δ5) and delta 6 (Δ6) desaturases 
Delta 5 and delta 6 are enzymes involved in the metabolic pathway of the long-chain 
polyunsaturated fatty acids. In the first and rate limiting step in the biosynthesis of n-6 and n-3 
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polyunsaturated fatty acids (PUFAs), the microsomal Δ6 desaturates the essential fatty acids 
linoleic acid (18:2n-6) and α-linolenic acid (18:3n-3). The product of these reaction, γ-
linolenic (18:3n-6) and stearidonic acids (18:4n-3), are elongated to dihomo- γ-linolenic acid 
(20:3n-6) and 20:4n-3, respectively. These fatty acids are then desaturated by Δ5 to generate 
arachidonic acid (20:4n-6) and 20:5n-3 (figure 1.8). Further elongation and desaturation take 
place before peroxisomal β-oxidation converts the product to their final state; 22:5n-6 and 
22:6n-3 at the end of the pathway (de Antueno, Knickle et al. 2001).  
 
 
Figure 1.8 Metabolic pathway of long-chain polyunsaturated fatty acids. Further elongation and desaturation 
from arachidonic acids to β-oxidation step and final products are not shown here. PUFAs, polyunsaturated fatty 
acids; fatty acids are designated with a number that refers to the number of carbons in the chain; the number after 
the colon indicates the number of double bonds and the n refers to the location of the nearest double bond from 
the methyl end (Knutzon, Thurmond et al. 1998). 
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1.7 Real-Time Polymerase Chain Reaction 
1.7.1 Detection of low-abundance mRNA 
Real-time reverse transcription polymerase chain reaction (RT-PCR) applying fluorescence 
dyes (for example SYBR Green I) is currently the most sensitive and precise method for 
detection of low-abundance mRNA, often obtained from limited tissues samples. This highly 
sensitive technique has become the method of choice for detecting mRNA (Bustin 2000). RT-
PCR method allows measurement of different type RNA level in the cell, based on the 
kinetics of the corresponding double-stranded cDNA amplification. The SYBR Green I dye 
binds to the minor groove of double –stranded DNA, and its fluorescence increases about 
100-fold. As the fluorescence signal is increasing it is recorded at early cycles of 
amplification (Nikitina, Nazarova et al. 2003). 
 
1.7.2 The theory behind Real-time PCR 
Real-time PCR is the technique of collecting data throughout the PCR reaction as it occurs; in 
addition carry out amplification and detection in one single step. All together makes it less 
labor-intensive than other quantitative PCR methods. This is achieved by using different 
fluorescent chemistries that correlate PCR product concentration to fluorescence intensity. 
Reactions are characterized by the point in PCR cycle where the target amplification is first 
detected. This point is usually referred to as the cycle threshold (Ct), the time at which 
fluorescence intensity is greater than background fluorescence. Consequently, the greater the 
quantity of target DNA in the starting material, the faster a signal will appear, yielding a 
lower Ct (Heid, Stevens et al. 1996). 
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OBJECTIVES 
 
The objectives for this thesis were: 
 
 
• To study peroxisome proliferator-activated receptor transcription regulation in 
Atlantic salmon head kidney cells in vitro. 
 
 
• To determine PPARs expression levels in tissues in vivo. 
 
 
• To test specific PPAR agonists and analyze expression of target genes. 
 
 
• To investigate possible toxic effects of PPAR agonists on Atlantic salmon head kidney 
cells. 
 
 
• Perform transfection studies to examine PPARγ. 
 
 
• To determine if SHK-1 and ASK cells are suitable in vitro models for PPARs studies 
in fish. 
 
 
• To analyse the specificity of a novel anti - PPARγ antibody. 
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2 MATERIALS 
 
2.1 Reagents and chemicals 
 
Amersham Biosciences, Buckinghamshire, UK 
• ECL plus western blotting detection system 
• HybondTM-P transfer membrane 
 
Applied Biosystems, NJ, USA 
• SYBR Green PCR Master Mix 
 
Arcus Produkter, Oslo, Norway 
• Alkohol, absolutt Prima (Ethanol) 
 
BDH VWR, England 
• Methanol 
 
BD Living Colors 
• Monoclonal  Antibody (JL-8) Anti-GFP antibody 
 
Bio-Rad, CA, USA 
• Laemmli Sample Buffer 
• Acrylamid 30% BIS solution 
 
Bio Whittaker, Wokingham, UK 
• Trypsin/EDTA 
• RPMI 1640 medium 
 
Calbiochem, Ca, USA 
• Tween 20 (oilyethylen sorbitan monolaurat) 
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Electron Microscopy Sciences, Hatfield, PA 
• Paraformaldehyde 16 %  
 
Eppendorf, Hamburg, Germany 
• Water, Molecular Biology Grade 
 
GIBCO BRL, Uxbridge,UK. 
• Foetal bovine serum (FBS) 
• Foetal calf serum (FCS) 
• Leibovitz’s L-15 medium (L-15) 
• 2-mercaptoethanol (2-ME) 
 
Invitrogen, Molecular Probes, Oregon, USA 
• Alexa Fluor® 488 phalloidin 
• Alexa Fluor® 568 phalloidin 
• Prolong® Gold antifade reagent with DAPI 
• Prolong® Gold antifade reagent 
 
Jackson Immuno Research Laboratories, Pennsylvania, USA 
• CyTM2-conjugate mouse anti rabbit IgG 
• CyTM3-conjugate mouse anti rabbit IgG 
 
Merck, Darmstadt, Germany 
• HCl 
• KCl 
• KH2PO4 
• NaCl 
• Na2HPO4 * 2H2O 
• Aceton 
 
Normilk AS, Levanger, Norway 
• Non-fat skimmed milk 
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Pierce, USA 
• Supersignal® West Femto Maximum sensitivity Substrate 
 
Sigma-Aldrich, St.Louis, USA 
• Bovint serum albumine (BSA) 
• Ammonium persulfat (APS) 
• Dimethylsulfoksid (DMSO) 
• Gentamicin Sulfate 
• L-Glutamine 
• Triton X-100 
• (N,N,N,N,-tetramethyl-Ethylendiamin) (TEMED) 
• Trypan Blue 
• Anti-Actin antibody produced in rabbit 
 
2.2 Kits 
Nucleofector® Solution (Amaxa Biosystems, USA) 
RNeasy® Mini Kit (Qiagen, MD, USA) 
RNase free DNase set (Qiagen, MD, USA) 
TaqMan® Reverse Transcription Reagents (Applied Biosystems, NJ, USA) 
 
2.3 Solutions 
Table 2.1: Phosphate buffered saline (PBS) pH 7, 4 (4 L) 
NaCl 
KCl 
KH2PO4 
Na2HPO4 * 2H2O 
MQ water 
32 g 
0,8 g 
1,08 g 
7,12 g 
3950 ml 
HCl To adjust pH to 7,4 
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Table 2.2: Tris/EDTA (TE) pH 7, 6 (20 ml) (to dissolve primer-concentrate) 
1 M Tris pH 7,6 
0,5 M EDTA pH 8,0 
MQ water 
0,2 ml 
0,04 ml 
19,76 ml 
 
Western blotting: 
Table 2.3: 10 % gel 
MQ water 
Lower gel buffer 
Acrylamid 
10 % APS 
TEMED 
1,5 ml 
0,9 ml 
1,2 ml 
18 µl 
1,8µl 
 
Table 2.4: Stacking gel 
MQ water 
Upper gel buffer 
Acrylamid 
10 % APS 
TEMED 
1,2 ml 
0,5 ml 
0,6 ml 
10 µl 
2 µl 
 
Table 2.5: TGS-buffer 
TGS x 10 (Bio-Rad) 
ddH2O water 
100 ml 
900 ml 
 
Table 2.6: TG blotting-buffer 
TG x 10 (Bio-Rad) 
Methanol 
ddH2O water 
100 ml 
200 ml 
700 ml 
 
Table 2.7: PBS-T (0, 1 %) 
PBS 
Tween 20 
500 ml 
500 µl 
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Table 2.8: Blocking solution (5 %) 
PBS 
Tween 20 
Non-fat skimmed milk 
10 ml 
10 µl 
500 µl  
 
Table 2.9: Stripping-buffer 
100 mM β-mercaptoethanol 
2 % (w/v) Sodium dodecyl sulphate (SDS) 
62,5 mM Tris-HCL pH 6,7 
390 µl 
5000 µl 
3125 µl 
 
 
2.4 Synthetic PPAR ligands 
 
Hypolipidemic agent 
• Fenofibrate 
 
Hypoglycemic agent (thiazolidinediones):  
• Rosiglitazone  
 
Fatty acyl-CoA dehydrogenase inhibitors: 
• Tetradecylthioacetic acid (TTA) 
  
(All ligands were dissolved and diluted in DMSO to concentration 100 mM) 
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2.5 Primers used for quantitative Real-time PCR 
Target gene Direction Sequence Primer efficiency
18S* F (5’-3’) 
R (5’-3’) 
TGTGCCGCTAGAGGTGAAATT 
GCAAATGCTTTCGCTTTCG 
1.00 
EF1-α* F (5’-3’) 
R (5’-3’) 
CACCACCGGCCATCTGATCTACAA 
TCAGCAGCCTCCTTCTCGAACTTC 
0.97 
PPAR-α** F (5’-3’) 
R (5’-3’) 
TCCTGGTGGCCTACGGATC 
CGTTGAATTTCATGGCGAACT 
1.99 
PPAR-β** F (5’-3’) 
R (5’-3’) 
GAGACGGTCAGGGAGCTCAC 
CCAGCAACCCGTCCTTGTT 
2.07 
PPAR-γBoth** F (5’-3’) 
R (5’-3’) 
CATTGTCAGCCTGTCCAGAC 
TTGCAGCCCTCACAGACATG 
2.04 
PPAR-γLong*** F (5’-3’) 
R (5’-3’) 
CATTGTCAGCCTGTCCAGAC 
TTGCAGCCCTCACAGACATG 
2.0 
PPAR-γShort*** F (5’-3’) 
R (5’-3’) 
ATACAGCGTGTATCAAGACG 
TTGCAGCCCTCACAGACATG 
2.0 
SR-BI** F (5’-3’) 
R (5’-3’) 
AACTCAGAGAAGAGGCCAAACTTG
TGCGGCGGTGATGATG 
1.99 
LPL** F (5’-3’) 
R (5’-3’) 
TGCTGGTAGCGGAGAAAGACAT 
CTGACCACCAGGAAGACACCAT 
2.0 
ACO** F (5’-3’) 
R (5’-3’) 
CCTTCATTGTACCTCTCCGCA 
CATTTCAACCTCATCAAAGCCAA 
2.03 
CD 36*** F (5’-3’) 
R (5’-3’) 
GGATGAACTCCCTGCATGTGA 
TGAGGCCAAAGTACTCGTCGA 
1.98 
Δ-5*** F (5’-3’) 
R (5’-3’) 
AGAGGCACTCCCACAGAAGC 
AGACCTTCCTGTCGATGACCA 
2.03 
Δ-6*** F (5’-3’) 
R (5’-3’) 
AGAGCGTAGCTGACACAGCG 
TCCTCGGTTCTCTCTGCTCC 
1.98 
Primers for quantitative Real-Time PCR used in the present thesis: 
*Already designed and tested by S.M Jørgensen (Jørgensen, Kleveland et al., 2006) 
**Already designed and tested by E.J Kleveland (Kleveland et al., 2006) 
***Designed by T.Gjøen and tested by A.L Rishovd (Department of Pharmaceutical Biosciences, School of 
Pharmacy, University of Oslo) 
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2.6 Cells 
• SHK-1 cell line (Salmon head kidney cells) was kindly provided by B. Dannevig 
(National Veterinary Institute, Oslo, Norway) 
• ASK cells (Atlantic salmon kidney cells) was kindly provided by B. Krossoy 
(Department of Fisheries and Marine Biology, University of Bergen, Norway) 
 
2.7 Plasmids and antibodies 
Cloned PPARγ-plasmids and salmon anti-PPARγ-antibodies were kindly provided by H. 
Sundvold (AKVAFORSK, Norwegian University of Life Sciences). 
 
Plasmids: 
• H10- sscPPARγ2 (cDNA from pig, served as a positive control) 
• H15- salPPARγwt (cDNA from salmon, this is the normal variant) 
• H16- salPPARγΔ (cDNA from salmon, a splicingvariant  with deletion) 
 
Salmon PPARγ antibodies: 
• PPI- preimmunt serum (produced in rabbit, and serve as a negative control) 
• SAB-final bleed (produced in rabbit, express target gene PPARγ )  
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3 METHODES 
 
3.1 Cultivations of cells 
SHK-1 cells (Salmon head kidney cells) and ASK cells (Atlantic salmon kidney cells) were 
cultured in Leibovitz L-15 medium supplemented with 50 µg ml-1 gentamicin, 4 mM L- 
glutamine, 40 µM β-mercaptoethanol, 5% foetal bovine serum for SHK-1 cells and 10 % 
foetal bovine serum for ASK cells. Cells were routinely split 1: 2,5 every 7-8 days for SHK-1 
cells and once every two weeks for ASK cells, both cell lines were maintained at 20°С. 
 
3.2 SHK-1 cells treated with PPAR ligands 
SHK-1 cells (4 * 105 cells, passages 60-70) were seeded in 25-cm2 flasks and cultured in L-15 
medium with supplements. 100 µM PPAR ligands were added 24 hours after seeding, and the 
cells were harvested at days 1 and 3 of post-treatment. The cells were washed carefully 3 
times with cold PBS before RNA isolation. 
 
3.3 RNA isolation of PPAR ligand treated SHK-1 
Total RNA from the SHK-1 cells was isolated using the RNeasy® Mini Kit from Qiagen 
(MD, USA). An on-column DNase digestion step was included to remove potential DNA 
contamination. All protocols were according to the manufacturer’s instructions. 
 
3.4 cDNA Synthesis 
All samples were reverse transcribed using TaqMan® Reverse Transcription Reagents 
(Applied Biosystems, CA, USA) according to the manufacturer’s protocols and with random 
hexamer primers. cDNA was made from 2 µg total RNA. In the last of the 3 experiments, the 
analyses were duplicated in the reverse-transcription step; this was done to test experimental 
variation in the reverse-transcription reaction. (Ståhlberg et al., 2004) 
 
The two-step RT PCR Reaction was performed with an Eppendorf Mastercycler Gradient.  
 
Thermal cycling parameters:  
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Incubation: 25°С for 10 minutes.    
RT: 48°С for 30 minutes. 
Reverse transcriptase inactivation: 95°С for 5 minutes. 
Cooling: 4°С for some minutes and then stored in -20°С 
 
3.5 Amplification 
Real-Time PCR was performed with the ABI Prism® 7000 system and gene-specific primers. 
A 2 x SYBR® Green PCR Mastermix, 0,4 µM of each primer, and the cDNA template were 
mixed in 25µl volumes. 
 
A two-step PCR was run for 40 cycles. 
PCR program used: 
Active1: 50°С for 2 minutes 
Active2: 95°С for 10 minutes 
Denaturation (40 x): 95°С for 15 seconds 
Annealing/extension (40 x): 60°С for 1 minute  
 
A dissociation curve was included in the PCR program to make sure that specific products 
were obtained in each run 
 
3.6 Data analyses and statistics 
Housekeeping genes were chosen based on the experimental findings of Jørgensen et al. 
(2006), where reference genes in Atlantic salmon were validated. By using housekeeping 
genes for relative expression analysis of Real-Time PCR data it is possible to investigate the 
effect of different treatments on gene expression. Relative expression of the different genes 
was determined using the Relative Expression Software Tool (REST) (Pfaffl, Horgan et al. 
2002) An analysis of gene expression in SHK-1 cells treated with PPAR ligands was 
performed, and normalized by the housekeeping genes 18S and EF1-α (Jorgensen, Kleveland 
et al. 2006) This  analysis sets expression level (ratio between target and housekeeping gene) 
in control group (untreated SHK-1 cells) to 1, and the changes in the test groups (fenofibrate 
and rosiglitazone) relative to this. Significant difference from expression in the control group 
was calculated by the Pair Wise Fixed Reallocation Randomization Test© (2000 
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randomizations) in the software. Mean values were used in REST, n = 3. Probability values 
(p) of < 0.05 were considered significant. 
 
3.7 Cell transfection 
Cells were cultivated to confluence in 175 cm2 flask. Cell solution was then trypsinized and 
equally divided in tubes, each with cell density at least 2 x 106 cells per nucleofection® 
sample. Cell culture tubes were centrifuged at 900 x g at room temperature for 10 minutes. 
Supernatant was discarded completely so that no medium covered the cell pellet. The pellet 
was resuspended in room temperature Nucleofector® Solution to a final concentraton of  2 x 
106 cells/100µl. DNA plasmids were added and the sample transferred into an amaxa certified 
cuvette. The sample was run in a Nucleofector ® using the program T-20. When the 
programme was finished the sample was removed from the cuvette. RPMI was added to 
resuspend the cells and it was transferred from the cuvettes back to tube with a specialised 
plastic pipette provided in the kit. Culture medium was added to the cells, and the cell 
medium was cultivated in 20°С. 
 
3.8 Immunofluorescence staining 
Cells were cultivated on coverslips in culture dish. The medium was removed and the cells 
washed with cold PBS. The cells were fixed with 4% PFA or 80% MeOH for 10 minutes. 
Cells were washed 3 times with PBS-T. PFA-fixed cells were incubated with PBS-/0, 1% 
Triton for 5 minutes while MeOH-fixed cells stayed in PBS. The coverslips were then 
blocked in 2% PBS/FCS for 45 minutes. 
 
Staining with antibody: 
Primary antibody was diluted 1:200 in 2% PBS/FCS. Coverslips were turned with cells side 
down over 30µl of antibody mixture and stained for at least 1 hour in room temperature. The 
coverslips were washed with 2% PBS/FCS three times, carefully. Phalloidin stock solution 
was first diluted 1: 40 with PBS and then 1:50 in 2% PBS/FCS. Secondary antibody was 
dissolved in 2% PBS/FCS/Phalloidin in a ratio of 1:200. The staining step was repeated with 
secondary antibody. The coverslips were washed with 2 % PBS/FCS 3 times before they were 
permanently mounted with a small drop of Fluorsave with or without DAPI on to objectsglas.  
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3.8 Phalloidin staining 
The cells on coverslips were washed twice with PBS, and then fixed with 4% PFA for 10 
minutes before repeating the washing procedure twice or more with PBS. The coverslips were 
extracted with cold acetone (-20°С) for 3-5 minutes and then washed twice or more with PBS. 
5µl phalloidin stock solution was dissolved in 200 µl PBS and then 1 %BSA was added to the 
staining solution. The cells were incubated in the solution for 30 minutes at room temperature 
in a covered container to avoid evaporation. The coverslips were washed with PBS and then 
permanently mounted with a drop of Fluorsave without DAPI on to objectsglas.  
 
3.9 SDS-PAGE and Western blotting 
SHK-1 cells transfected with cloned PPARγ plasmids and control cells were seeded in culture 
dish for 6 days. The medium was removed and the cells washed with cold PBS. A solution of 
Laemmli sample buffer and 2-ME were added to the cell-culture dish. The lysate was 
collected with a rubber policeman and homogenized with pipette. The samples were heated in 
95°С for 5 minutes before they were separated on a 10% SDS-PAGE gel and blotted on to a 
Hybond-P membrane, using electro blotting. The membranes were then blocked in 5% non-
fat skimmed milk-0, 1% PBS-T for 1 hour. The membranes were then incubated with primary 
antibodies in their suitable dilution ratio for at least 2 hours in room temperature. All 
membranes were washed 3 times in 0, 1% PBS-T and then incubated with a secondary 
antibody. All membranes were washed again 3 times in 0, 1% PBS-T. Chemiluminescence 
was detected using ECL plus and Supersignal® West Femto detection reagents.   
 
3.10 Cell viability assay 
Cells were cultured and treated with PPAR ligands as described above. Trypan blue were 
diluted in PBS in a ratio of 1:1. On days 1, 3 and 5 of post-treatment, the medium was 
removed and trypan blue/PBS was added to the cells for 5 minutes. After incubation the 
solution were removed and PBS were added to the culture dish. The cells were examined in 
fluorescence microscope for cell death. 
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4 RESULTS 
 
4.1 Relative expression of PPAR genes in Atlantic salmon tissues 
In order to find the relative distribution of individual PPARs in tissues of Atlantic salmon, 
cDNA of liver, gills and head kidney from 9 fish were tested. The expression of liver and 
head kidney (two relevant tissues) and gills (less relevant) were investigated by performing 
quantitative Real-Time PCR. This was to quantify of the variation in expression of PPARγ wt 
and PPARγ with deletion. Nine fish were analysed for PPAR alpha, beta, gamma long 
(normal variant) and gamma short (splicingvariant with deletion). The expression was 
normalized by reference genes 18S and EF1-α in liver, gills and head kidney (Jorgensen, 
Kleveland et al. 2006). REST© analysis of the Real-Time PCR data showed that there was a 
significantly lower expression of all PPARs in gills compared to liver.  The average 
expression level in head kidney was also apparently lower than in liver, but this difference 
was not significant (figure 4.1). 
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Fig.4.1 Relative expression of PPAR genes in head kidney cells (A) and in gill cells (B) from 9 Atlantic 
salmon. Relative expression was calculated using the REST© algorithm and the Pair Wise Fixed Reallocation 
Randomization Test©, (p) <0, 05, n = 1. Asterisk (*) above bar denotes significant difference from expression in 
control cells (liver cells). Abbreviations: PPAR-a, b, g, peroxisome proliferator-activated receptor alpha, beta, 
gamma. 
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4.2 Relative expression of PPAR genes in different cell lines 
To investigate the expression level of PPARs in different cell lines, and whether they are 
suitable models for studies of PPAR-regulated genes, we compared the mRNA levels in ASK 
and SHK-1 muscle and liver tissue samples (liver as normalized samples). PPAR alpha 
expression was higher in cell lines and muscle. No significant difference was found for PPAR 
beta, whereas a significantly lower expression was found in for PPAR gamma long and short 
in all samples compared to liver. Muscle tissue displayed in general the lowest expression 
(figure 4.2).  
 
Figure 4.2. Relative expression of PPAR genes in ASK and SHK-1 cells, muscle and liver tissue. Relative 
expression was calculated using the REST© algorithm. Asterisk (*) above bar denotes significant difference from 
expression in liver tissue calculated by the Pair Wise Fixed Reallocation Randomization Test©, (p) <0, 05, n = 1. 
Abbreviations: PPAR-a, b, g, peroxisome proliferator-activated receptor alpha, beta, gamma. 
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4.3 Relative expression of relevant genes in lipid metabolism in different cell  
To investigate expression of PPAR target genes in cell lines, we investigated the relative 
expression of four target genes SR-BI, LPL, ACO and CD 36 (figure 4.3). 
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Figure 4.3 Relative expression of target genes in cell tissue and lines; liver, muscle, ASK and SHK-1. 
Relative expression was calculated using the REST© algorithm and the Pair Wise Fixed Reallocation 
Randomization Test©, (p) <0, 05, n = 2. All the samples are significant down-regulated compared to liver 
(control sample). Abbreviations; SR-BI, Scavenger Receptor class B; LPL, Lipoprotein Lipase; ACO, Acyl-CoA 
Oxidase; CD 36, Scavenger Receptor class B submember. 
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4.4 Comparative pilot of ASK and SHK-1 
To investigate possible differences between cell lines, a comparable experiment was 
conducted with ASK and SHK-1. Both cell lines were seeded and treated with 100 µM TTA 
for 3 days at 20°С. PPAR genes and target genes in ASK and SHK-1 cells were expressed at 
comparable levels in both cell lines. The relative expression in both cell lines gave almost the 
same values, with the exception of LPL, where ASK cells showed a down-regulation whereas 
SHK did not (figure 4.4).       
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Figure 4.4. Relative expression of PPAR genes and target genes in ASK and SHK-1 cells. Relative 
expression was calculated using the REST© algorithm. Asterisk (*) above bar denotes significant difference from 
expression in control cells (un-treated cells) calculated by the Pair Wise Fixed Reallocation Randomization 
Test©, (p) <0, 05, n = 2. Abbreviations: PPAR-a, b, g, peroxisome proliferator-activated receptor alpha, beta, 
gamma; SR-BI, Scavenger Receptor class B; LPL, Lipoprotein Lipase; ACO, Acyl-CoA Oxidase. 
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4.5 Morphology changes in cell lines after treatment with PPAR ligands 
To see if treatment with 100 µM PPAR ligands could have any toxic effect on the cells, we 
analysed changes in morphology of both cell lines, ASK and SHK-1. Cells were cultivated on 
coverslips for 24 hours and then treated with PPAR ligands for 1, 3 and 5 days. After 
treatment, the cells were formaldehyde-fixed, stained with Alexa-phalloidin and examined for 
morphology changes by confocal microscopy. ASK cells remained well spread out and 
unchanged throughout the trial period with fenofibrate and roziglitazone, whereas SHK-1 
cells treated with rosiglitazone, showed morphology changes. The cells were changed from a 
star shaped morphology to more round up and starting to detach from the substrate. Both ASK 
and SHK-1 cells displayed morphology changes in the presence of 100 µM TTA (figure 4.5 
and 4.6). At this concentration, lipid droplets could be observed in the medium and the cells 
started to detach from the coverslips. 
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Figure 4.5 Morphology changes in ASK cells. Confocal micrographs of untreated ASK cells (24, 72 and 120 
hours) under control culture conditions (A), and following treatment with 100 µM PPAR ligands; Fenofibrate 
(B), Rosiglitazone (C) and TTA (D). This data is representative of n = 3 separate experiments. Cell passages 60-
70. Stained with Alexa Fluor® 488 Phalloidin (red). 
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Figure 4.6 Morphology changes in SHK-1 cells. Confocal micrographs of untreated SHK-1 cells (24, 72 and 
120 hours) under control culture conditions (A), and following treatment with 100 µM PPAR ligands; 
Fenofibrate (B), Rosiglitazone (C) and TTA (D). This data is representative of n = 3 separate experiments. Cell 
passages 75-80. Stained with Alexa Fluor® 568 Phalloidin (green). 
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4.6 Effect of PPAR ligands on cell viability 
To see if treatment with 100 µM PPAR ligands induces cell deaths, ASK and SHK-1 cells 
were cultivated in culture dish for 24 hours and treated with PPAR ligands for 1, 3 and 5 days. 
After days 1, 3 and 5 of post-treatment, the cells were stained with trypan blue and examined 
for dye uptake (cell death) by microscopy (figure 4.7 and 4.8). 
 
   
 
    
 
   
 
   
 
Figure 4.7 Trypan blue staining of ASK cells. Micrographs of untreated ASK cells (1, 3 and 5 days) under 
control culture conditions (A), and following treatment with 100 µM PPAR ligands; Fenofibrate (B), 
Rosiglitazone (C) and TTA (D).  
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Figure 4.8 Trypan blue staining of SHK-1 cells. Micrographs of untreated ASK cells (1, 3 and 5 days) under 
control culture conditions (A), and following treatment with 100 µM PPAR ligands; Fenofibrate (B), 
Rosiglitazone (C) and TTA (D).  
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Table 4.1: Cell death in ASK cells 
Treatment % cell death 24 hours % cell death 72 hours % cell death 120 hours 
Control 0 0 0 
Fenofibrate 0 5,19 16,98 
Rosiglitazone 0 1,23 3,33 
TTA 1,63 14,28 3,84 
 
Table 4.2: Cell death in SHK-1 cells 
Treatment % cell death 24 hours % cell death 72 hours % cell death 120 hours 
Control 0 0 0 
Fenofibrate 0 6,81 64,48 
Rosiglitazone 3,22 4 4,39 
TTA 0 8,45 3,57 
 
 
4.7 Effect of PPAR agonists on gene expression in SHK-1 cells 
To investigate the effects of treatment with PPAR ligands on cells, cDNA of SHK-1 cells 
treated with 100 µM fenofibrate and rosigliazone for 24 and 72 hours were analyzed with a 
set of gene specific primers. The mRNA levels of some genes coding for important proteins in 
lipid metabolism was investigated by quantitative Real-Time PCR. The samples were 
normalized by the reference genes 18S and EF1-α. In SHK-1 cells treated with fenofibrate for 
24 and 72 hours only PPAR gamma short gene at 72 hours showed a down-regulation. SHK-1 
cells treated with rosiglitazone for 24 hours showed a significant up-regulation of SR-BI, 
ACO and CD 36, whereas LPL was down regulated. In cells treated with rosiglitazone a 
significant up-regulation of SR-BI and CD 36 were observed after 72 h (figure 4.9). 
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Figure 4.9 Relative expression of genes involved in lipid metabolism in Atlantic salmon head kidney cells 
(SHK-1) after treatment with PPAR ligands. SHK-1 cells treated with fenofibrate for 24 hours (A) and 72 
hours (B), and SHK-1 cells treated with rosiglitazone for 24 hours (C) and 72 hours (D) were maintained at 
20°С. Relative expression was calculated using the REST© algorithm. Asterisk (*) above bar denotes significant 
difference from expression in control cells (untreated SHK-1 cells) calculated by the Pair Wise Fixed 
Reallocation Randomization Test©, (p) <0, 05, n = 3. Abbreviations: PPAR-a,b,g, peroxisome proliferator-
activated receptor alpha, beta, gamma; SR-BI, Scavenger Receptor class B; ACO, Acyl-CoA Oxidase; LPL, 
Lipoprotein Lipase; CD 36, Scavenger Receptor class B antigen; Delta 5,6, Fatty acid desaturase. 
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4.8 Alignments 
Two splice variants of PPARγ have been identified (H.Sundvold unpublished). These cDNAs 
have been cloned into pCMV-script (expression vector) and called H15 (long) and H16 
(short). H16 is the short splicing variant missing 34 aa of A/B domain (coded from exon 3) 
(see BLAST search figure 4.9). In addition, a PPARγ cDNA (H10) from pig were also 
available, and served as a control. 
 
BLAST comparison of H15 and H16 
 
 Score =  971 bits (2511),  Expect = 0.0 
 Identities = 515/549 (93%), Positives = 515/549 (93%), Gaps = 34/549 (6%) 
 
H15  1    VSSYPEMVDTRRAAWSLLSFGLGTLDLVEMDNKMNSFDMKTLSTLDYPYLPSLEYSHNSP   
H16  1    VSSYPEMVDTRRAAWSLLSFGLGTLDLVEMDNKMNSFDMKTLSTLDYPYLPSLEYSHNSP   
 
H15  61   HHHHSPDRSHSCNHSPDRSHSFNHSPDRSHSFNHSPDRNHSFNHSPDRSHSFNHSPDRSH        
H16  61   HHHHSPDRSHSCNHSPDRSHSFNHSPDRSHSFNHSPDRNHSFNHSPDRSHSFNHSPDRSH   
 
H15  121  SYNDTYSVYQGSVNDKPLSPSQSSDCSIVSLSRPRPHSNPPTYTDASSLLNIDCRVCGDK   
H16  121  SYNDTYSVYQ----------------------------------DASSLLNIDCRVCGDK  
 
H15  181  ASGFHYGVHVCEGCKGFFRRTVRLKLVYDHCDLHCRIHKKSRNKCQYCRFQKCLLVGMSH              
H16  147  ASGFHYGVHVCEGCKGFFRRTVRLKLVYDHCDLHCRIHKKSRNKCQYCRFQKCLLVGMSH   
 
H15  241  DAIRFGRMPQVEREKLLQAEFMDVEPRNPESADLRALSRQLCLSYHRHFPLTKSKAKAIL   
H16  207  DAIRFGRMPQVEREKLLQAEFMDVEPRNPESADLRALSRQLCLSYHRHFPLTKSKAKAIL   
 
H15  301  SGKTHGNSPFVIHDMKSLTAGQYFINCRQLPVLERQRSVLPPEEPAEELELSVFRRIQFR               
H16  267  SGKTHGNSPFVIHDMKSLTAGQYFINCRQLPVLERQRSVLPPEEPAEELELSVFRRIQFR   
 
H15  361  SAEAVQEVTEFTKSIPGFTELDMNDQVILLKYGVIEVMTTMLAPLMNKDGTLFAYGQIFM           
H16  327  SAEAVQEVTEFTKSIPGFTELDMNDQVILLKYGVIEVMTTMLAPLMNKDGTLFAYGQIFM   
 
H15  421  TREFLKSLRKPFCEMMEPKFEFAAKFNLLELDDSDMALFFAVIILSGDRPGLVNVKPIED               
H16  387  TREFLKSLRKPFCEMMEPKFEFAAKFNLLELDDSDMALFFAVIILSGDRPGLVNVKPIED   
 
H15  481  LQETVLQALELQLKTIHPDCPQLFAKLLQKMTDLRQLVANHVRHIHLLKKQELQMCLHPL   
H16  447  LQETVLQALELQLKTIHPDCPQLFAKLLQKMTDLRQLVANHVRHIHLLKKQELQMCLHPL   
 
H15  541  LQEIMRDLY  549 
H16  507  LQEIMRDLY  515 
 
Figure 4.10 Alignment. BLAST search shows that the two genes, H15 and H16 are similar with the exception 
of 34 amino acids (aa) missing at the position 121 aa in H16. 
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4.9 SHK-1 cell transfection 
SHK-1 cells were transfected with pmaxGFPTM, H10, H15 and H16 plasmids. The 
transfection efficiency observed in SHK-1 cells transfected with pmaxGFPTM plasmid with a 
fluorescence microscope was estimated to about 2%. The transfected cells were cultivated in 
20°С for 1 and 3 days before RNA isolation and cDNA synthesis. Using splice variant 
specific primers we could demonstrate that the two cDNA’s were expressed in the cells after 
transfection (figure 4.11).  
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Figure 4.11 Relative expression of PPARγ splice variants in SHK-1 cells transfected with PPARγ 
plasmids. SHK-1 cells transfected with plasmid H15 (long) for 24 hours (A) and 72 hours (B), and SHK-1 cells 
transfected with plasmid H16 (short) for 24 hours (C) and 72 hours (D) were all maintained at 20°С. Relative 
expression was calculated using the REST© algorithm. Asterisk (*) above bar denotes significant difference from 
expression in control cells (non-transfected SHK-1 cells) calculated by the Pair Wise Fixed Reallocation 
Randomization Test©, (p) <0, 05, n = 2. Abbreviations: PPAR-a, b, g, peroxisome proliferator-activated receptor 
alpha, beta, gamma. 
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4.10 SHK-1 cell transfection  
Gene expression analysis in SHK-1 cells transfected with H15 and H16 showed an up-
regulation of some genes in the 24 hours samples, and a down-regulation in the 72 hours 
samples. The 24 hours H15 transfected cells showed an up-regulation of SR-BI, ACO and CD 
36 genes, while in the 72 hours H15 transfected cells, none of these genes were up-regulated. 
LPL, Delta 5 and Delta 6 were down-regulated. After 24 hours, H16 transfected cells showed 
an up-regulation of SR-BI and CD 36. A down-regulation of LPL, ACO, Delta 5 and Delta 6 
was seen after 72 hours in H16 transfected cells (figure 4.12). 
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Figure 4.12. Relative expression of some relevant genes in lipid metabolism in SHK-1 cells transfected 
with cloned PPARy plasmids. SHK-1 cells transfected with plasmid H15 (long) for 24 hours (A) and 72 hours 
(B), and SHK-1 cells transfected with plasmid H16 (short) for 24 hours (C) and 72 hours (D) were all maintained 
at 20°С. Relative expression was calculated using the REST© algorithm. Asterisk (*) above bar denotes 
significant difference from expression in control cells (non-transfected SHK-1 cells) calculated by the Pair Wise 
Fixed Reallocation Randomization Test©, (p) <0, 05, n = 2. Abbreviations: SR-BI, Scavenger Receptor class B; 
LPL, Lipoprotein Lipase; ACO, Acyl-CoA Oxidase; CD 36, Scavenger Receptor class B member; Delta 5,6, 
Fatty acid desaturase. 
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4.11 Analysis of PPARγ expression with peptide antiserum 
SHK-1 cells were transfected with PPARγ and pmaxGFPTM cDNA’s as described and 
cultured for 6 days at 20°С. A peptide antibody anti- PPARγ was tested with western blotting 
to test if PPARγ was increased in the samples transfected with PPARγ plasmids. The samples 
(pmaxGFPTM, H10, H15, H16 and control) were subjected to SDS-PAGE (10%) in equal 
amounts (20µg). The membrane was incubated with primary PPARγ antibody in a 1:1000 
dilution for 2 hours in room temperature, and secondary antibody mouse anti rabbit HRP was 
run in a 1:10000 dilution ratio for 1 hour. The antibody detected 2 major bands at 50 and 60 
kDa in all the samples, and the control and pmaxGFPTM samples had bands with signal 
strengths similar to samples transfected with PPARγ plasmid (figure 4.13). Liver protein was 
also tested with same antibody PPARγ and showed same bands as samples transfected with 
PPARγ plasmids (figure 4.14). Transfection did therefore not seem to increase a specific 
PPARγ signal in these samples. 
 
                 Control                H16                    H15               H10             pmaxGFPTM 
 
Figure 4.13 Western blot analysis of SHK-1 cells transfected with GFP and  PPARy plasmids. 
The membrane was incubated with primary anti-PPARy antibody in a 1:1000 dilution for 2 hours in room 
temperature and with secondary mouse anti-rabbit HRP antibody in a 1:10000 for 1 hour in room temperature. 
The proteins were visualized with chemiluminescence detection (ECL plus), and the photo negative exposed for 
5 seconds. All the samples detected 2 bands at approximately 50- and 60 kDa. The experiment was repeated 3 
times. 
                          Liver 
 
Figure 4.14 Western blot analysis of fish liver proteins. The membrane was incubated with primary anti-
PPARy antibody in a 1:1000 dilution for 2 hours in room temperature and with secondary mouse anti-rabbit 
HRP antibody in a 1:10000 for 1 hour in room temperature. The proteins were visualized with 
chemiluminescence detection (ECL plus), and the photo negative exposed for 5 seconds. The sample detected 2 
bands at approximately 50- and 60 kDa. The experiment was repeated 2 times. 
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The same samples were tested with anti-GFP antibody. The membrane was incubated with 
primary anti-GFP antibody in a 1:5000 dilution for 2 hours in room temperature and 
secondary antibody rabbit anti mouse HRP was run in a 1:50000 dilution ratio for 1 hour. The 
western blot detected 2 major bands at 27 and 30 kDa in the pmaxGFPTM sample but not in 
the other samples (figure 4.15). 
 
  (A)          pmaxGFPTM     (B)           pmaxGFPTM        H10                H15                    H16 
  
Figure 4.15 Western blot analysis of SHK-1 cells transfected with GFP and  PPARy plasmids. 
The membrane was incubated with primary anti-GFP antibody in a 1:5000 dilution for 2 hours in room 
temperature and with secondary rabbit anti-mouse HRP antibody in a 1:50000 for 1 hour in room temperature. 
The proteins were visualized with chemiluminescence detection (Supersignal® West Femto Maximum sensitivity 
Substrate), and the photo negative exposed for 5 minutes (A) and 5 seconds (B). Sample (A) is the same as the 
pmaxGFPTM sample in (B). The pmaxGFPTM sample detected 2 bands at approximately 27- and 30 kDa. The 
experiment was repeated 3 times. 
 
 
Sample loading was tested by western blot using an anti-actin antibody. The membrane was 
run in blocking buffer for an hour in room temperature before incubated with primary anti-
Actin antibody in a 1:500 dilution for 2 hours in room temperature, and secondary antibody 
mouse anti-rabbit HRP were run in a 1:20000 dilution ratio for 1 hour. The western blot 
detected 1 major band at 42 kDa in all the samples (figure 4.16). 
 
    Control               H10               H15                    H16 
 
Figure 4.16.Western blot analysis of SHK-1 cells transfected with  PPARy plasmids. 
The membrane was incubated with primary anti-Actin antibody in a 1:500 dilution for 2 hours in room 
temperature and with secondary mouse anti-rabbit HRP antibody in a 1:0000 for 1 hour in room temperature. 
The proteins were visualized with chemiluminescence detection (ECL plus), and the photo negative exposed for 
5 seconds. All the samples detected a band at approximately 42 kDa. The experiment was repeated 3 times. 
 51
4.12 Immunofluorescence staining of cells transfected with PPARy plasmids 
Transfected cells (ASK and SHK-1) were cultured on coverslips for 6 days and stained with 
PPARγ antibody. The samples were examined in confocal microscope to see if the antibody 
reacted with transfected PPARγ cells. Cells transfected with pmaxGFPTM-plasmids were 
included and served as a positive control of transfection efficiency. In the pmaxGFPTM 
transfected cell samples, only a few (1-2 cells) out of a hundred cells were positive. When 
cells transfected with PPARγ plasmids and control cells were scanned with the same settings, 
no differences in fluorescent signal could be observed. Counterstaining with DAPI revealed 
that all cells were stained, suggesting that the signal either was non-specific, or from 
endogenous PPAR. There were no differences between the ASK and the SHK-1 cell lines 
(figure 4.17 and 4.18). 
 
ASK CELLS TRANSFECTED WITH PLASMID (6 DAYS) 
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Figure 4.17 PPARy expressions in ASK cells transfected with cloned PPARy plasmids and cultivated for 6 
days at 20°С. Immunofluorescence micrographs of pmaxGFPTM transfected cells (A), under control culture 
conditions (B), transfected with H10 plasmids (C), transfected with H15 plasmids (D) and transfected with H16 
plasmids (E). 
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SHK-1 CELLS TRANSFECTED WITH PLASMID (6 DAYS) 
 
 
 
 
 
Figure 4.18 PPARγ expressions in SHK-1 cells transfected with  PPARγ plasmids and cultivated for 6 
days at 20°С. Immunofluorescence micrographs of pmaxGFPTM transfected cells (A), under control culture 
conditions (B), transfected with H10 plasmids (C), transfected with H15 plasmids(D) and transfected with H16 
plasmids(E). 
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4.13 Immunofluorescence staining of SHK-1 transfected with PPARγ plasmids 
Due to low transfection efficiency, transfected SHK-1 cells were cultured and grown on 
coverslips in culture dish for 3 weeks at 20°С before they were stained with PPARγ antibody 
and examined in confocal microscope. Although the ratio for transfected cells was higher 
(approximately 4-5 cells out of a hundred cells) due to longer cultivation time, the results 
were the same as for transfected cells cultivated for 6 days (figure 4.19). 
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SHK-1 CELLS TRANSFECTED WITH PLASMID (3 WEEKS) 
 
 
 
 
 
 
Figure 4.19 PPARγ expressions in SHK-1 cells transfected with  PPARγ plasmids and cultivated for 21 
days at 20°С. Immunofluorescence micrographs of pmaxGFPTM transfected cells (A), under control culture 
conditions (B), transfected with H10 plasmids (C), transfected with H15 plasmids (D) and transfected with H16 
plasmids (E). 
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4.14 Immunofluorescence staining of ASK treated with rosiglitazone 
In order to investigate whether ASK cells respond to PPARγ agonists by receptor activation 
and translocation of the receptor from the cytoplasm to nucleus, ASK cells were cultured on 
coverslips for 24 hours and then treated with 100 µM rosiglitazone for 24 and 72 hours. ASK 
cells were chosen due to their larger size and flattened morphology.  After treatment, the cells 
were fixed and stained with preimmune serum and PPARγ antiserum (PPI and SAB, 
respectively) and examined in confocal microscope to analyse for relocalization. One group 
were fixed with 4% PFA and one with 80% MeOH. There were no observations of 
relocalization of PPARγ to nucleus in either group and cells treated with primary antibody 
were all stained throughout the cell (figure 4.20 and 4.21). Figures of ASK cells treated for 24 
hours are not shown here. They displayed no difference compared to cells treated for 72 
hours. 
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IMMUNOFLUORESCENCE STAINING 4 % PFA-FIXED  
 
 
 
Figure 4.20 ASK cells under control culture conditions and after treatment with rosiglitazone were fixed 
with 4 % PFA and stained by immunofluorescence.  Using preimmune serum (A) anti-PPARy antiserum (B) 
or only with secondary antibody (C). This data is representative of n = 5 separate experiments. 
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IMMUNOFLUORESCENSE STAINING 80% MeOH-FIXED   
 
 
 
Figure 4.21 ASK cells under control culture conditions and after treatment with rosiglitazone were fixed 
with 80 % MeOH and stained by immunofluorescence.  Using preimmune serum (A) anti-PPARy antiserum 
(B) or only with secondary antibody (C). This data is representative of n = 5 separate experiments. 
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5 DISCUSSION 
 
5.1 Methodology 
5.1.1 Quantitative Real-time Polymerase chain reaction 
The main focus in this thesis was to examine PPAR transcription regulation in Atlantic 
salmon head kidney cells. Quantitative real-time polymerase chain reaction (qRT-PCR) 
studies are frequently used for this purpose. Quantitative RT-PCR technology is a more robust 
and accurate procedure to study gene expression than conventional methods. It is of particular 
value for expression studies in fish because the availability of highly specific antibodies is 
still limited. qRT-PCR is now considered as one of the most important methods for rapidly 
and quantitatively analyzing a number of transcripts from multiple samples in a multiplex 
format. It is the predominant technique for measuring mRNA levels of low copy number 
targets of interest. Furthermore, the advantage over conventional methods are a broader 
dynamic range and high reproducibility (Gibson, Heid et al. 1996; Heid, Stevens et al. 1996).  
Another major improvement is the ability to normalize data accurately. In order to 
compensate for errors that may occur during quantification of mRNA transcripts, 
nonregulated housekeeping genes are amplified simultaneously with target gene to serve as 
internal reference to which other RNA values can be normalized (Karge, Schaefer et al. 
1998). In this thesis 18S and EF1-α were applied as reference gene due to the fact that they 
are proven to be robust for in vivo and in vitro normalization of real-time PCR studies in 
Atlantic salmon specifically (Jorgensen, Kleveland et al. 2006). 
 
5.1.2 Cell transfection 
Transfection studies were also performed during this thesis. Transfecting PPARγ plasmid 
(H15 and H16) into Atlantic salmon cells makes it possible to investigate the transcriptional 
activity of this particular gene and analyze expression of PPARγ. Transfection studies could 
reveal important information about the activity in a particular gene. In this case, cDNA 
construct of two PPARγ splice variants were cloned into pCMV-script (expression vector) 
and transfected into Atlantic salmon cells with the Nucleofection® method (amaxa 
biosystems). Most transfection methods are optimized for mammalian cell lines, very few 
studies are seen using fish cell lines. The experience from previous studies has shown that it is 
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difficult to obtain high transfection efficiencies in fish compared to mammalian cell line. This 
was also the case in our experiment. To achieve high transfection efficiency, it is necessary to 
optimalize the transfection method for fish. 
 
The transfections in this study were performed by the Nucleofector technology method 
(amaxa biosystems). It is a simple and effective procedure. The principle behind this non-viral 
method is based on exposure of the cells to a combination of electrical parameters that allows 
DNA to be rapidly absorbed into the cells. This allows transfected DNA to directly enter the 
nucleus; it does not rely on cell division as other commonly used non-viral transfection 
methods. As DNA can directly enter the nucleus, very high transfection efficiency can be 
obtained in otherwise difficult-to-transfect-cells like immortal culture cell lines. Cell division 
is not crucial for DNA entry into the nucleus, this makes the time until transgene expression 
significantly shortened, and the experiment can be performed quickly and within a day. 
 
The nucleofector technology is based on electroporation of the cell and as DNA enters the 
nucleus directly, expression of transfected protein can be detected shortly after. Although, 
there are factors that limit the transfection efficiency that should be considered. It is of some 
importance that the cells are in exponential growth phase when transfections are performed, 
as this increases the transfection efficiency. The cells undergo mitosis immediately after the 
transfection and give rapid nuclear entry of DNA into the cells. This can be achieved by 
keeping the adherent cells subconfluent in culture flask, as this allows one more cell doubling. 
 
The efficiency of transient transfection is also determined by the cell line. Different lines of 
culture cells vary in their ability to take up and express exogenously added DNA. In our 
experiment, SHK-1 and ASK cells were used, earlier experiment have shown that Atlantic 
salmon fish cell line are harder to transfect than most mammalian cells.  
 
All data presented in this study are based on in vitro experiments. Transfection is an important 
tool to study transcriptional activity in a particular gene; however there are limitation related 
to transfection as a method. Transfection studies alone will not give information of mRNA, 
protein expression in distinct tissues or how a protein is regulated upon physiological 
conditions, when compared to in vivo studies. A complete picture can only be obtained when 
in vivo and in vitro studies are combined.  
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5.1.3 Cell culture 
The main difference between using cultured cells grown in vitro (SHK-1 and ASK cells) and 
the use of an intact animal or an isolated preparation, is that cultured cells provide a more 
controlled and easily manipulated environment than what is possible to achieve with an intact 
animal. With cultured cells, there are fewer problems concerning access to the cells of interest 
and distribution of pharmacological agents. Removing worries like whether or not the liver is 
metabolizing the substance of interest, makes it possible to control the concentration of an 
exogenous substance in the vicinity of the cells of interest. It is also possible to selectively 
alter a single experimental variable and evaluate its effect on a cell with much less concern 
about possible indirect effect from other systems.  
 
SHK-1 and ASK cells are immortal secondary cell lines. They can be grown and propagated 
in vitro for many years, and the advantage is that they provide a more homogeneous source of 
cell material than primary cultures, which are cells harvested from a subject, dissociated, and 
plated into a culture dish where they do not survive for a very long time. In addition, 
secondary clonal cell lines can be grown in essentially unlimited quantities, which is 
advantageous when there is need for large amount of cells for biochemical analyses and 
transfection procedures. However, the fact that the cells can grow indefinitely, implies that 
they have lost some of the differentiated properties of normal cells, and are acting like cancer 
cells. In addition, cells that replicate numerous of time are prone to mutations. This must be 
taken into account and caution must be used when applying the collected information back to 
cells of intact organism. 
 
In our experiment concerning cell morphology, changes were observed in SHK-1 cells treated 
with rosiglitazone. The cell passage had exceeded 80, a high passage number for this cell line, 
and the conformation changes observed could be a result of this, and not by ligand treatment 
alone.  
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5.1.4 Trypan blue exclusion viability test 
Trypan blue cell stain was observed after incubation of cells treated with ligand for different 
exposure time. This was particularly evident in cells treated with fenofibrate for 120 hours (5 
days). Trypan blue is a non-invasive stain used to selectively colour dead tissues and cells 
blue. Live cells with intact membranes will not be coloured since the reactivity of trypan blue 
is based on the chromopore being negatively charged, there will be no interaction unless the 
membrane is damaged. Therefore, only cells that exclude the dye are viable (Freshney, 
R,.1987). 
 
The incubation of trypan blue for 5 minutes appeared to have no significant effect on control 
cells. All cells in control cultures were viable, showing that trypan blue at this concentration 
do not have a toxic effect on SHK-1 and ASK cells. This indicates that the fenofibrate 
concentration used in this study was toxic to fish cell lines. Other studies have shown that 
fenofibrate in higher concentration than 50 µM induces cell cycle arrest and apoptosis in 
Ishikawa cells (Saidi, Holland et al. 2006). The cell line Ishikawa is established from an 
endometrial adenocarcinoma. Although different in many aspects, the Atlantic salmon cell 
lines behave like cancer cells, and it is tempting to hypothesize that fenofibrate induce cell 
death in ASK and SHK-1 cells at twice as high concentration.  
 
If the PPAR agonist concentration employed here are toxic towards SHK-1 and ASK cells, 
dead cells would be prone to detach and be washed away during preparation. Only stained 
cells that still stay onto the surface will be accounted for. With this in mind, the results 
probably underestimate the number of cell deaths. Using a method with a hemocytometer may 
be a solution to this problem. 
 
Before staining, the cells were cultered and grown to 100% confluence. After removing 
medium and staining with trypan blue, the cell confluence was decreased to 30-40 %. The 
staining procedure itself therefore seems to induce cell detachment from the substrate creating 
an underestimation of dead cells in the culture. 
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5.1.5 Protein detection 
The use of Western blotting is of great value in immunodetection of proteins. Western 
blotting, also called immunoblotting, is a powerful procedure for detection of proteins post-
electrophoresis, in particularly in our case when the abundance of fish proteins is low. The 
usefulness of these methods relies on the ability to provide simultaneous resolution of 
multiple immunogenic antigens within sample, which is different from the majority of 
immunochemical methods. 
 
Western blotting is effective only when an appropriate detection method is applied. 
Chemiluminescence method provides the advantageous possibility of re-exposing the blots to 
obtain suitable intensity for purposes of comparison (Kurien and Scofield 2006). When 
correctly applied, western blotting is a reliable method for protein detection.  
 
5.2 GENERAL DISCUSSION OF THE RESULTS 
 
PPARs and their ligands have since their discovery kept on fascinating due to their regulatory 
mode of action of lipids as direct modulators of gene expression. Even though PPARs are one 
of the most studied nuclear receptors, the knowledge about these receptors is still limited in 
fish. 
 
Compelling evidence that PPARα and PPARγ act at crucial nodes of the regulatory network 
to achieve energy homeostasis in the organism, and that lipid mediators like eicosanoids are 
natural PPAR ligands, give rise to the belief that many aspects of PPAR action are yet to be 
uncovered.  
 
The activation of PPARs can occur through a broad spectrum of ligands with rather low 
affinity. This implies that care must be taken when assessing the PPAR dependence of given 
signalling pathway. 
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5.2.1 Tissue expression of PPARs in Atlantic salmon 
The analysis of PPAR mRNA expression in head kidney and gills compared to liver showed 
that of PPAR mRNA levels were lower in in head kidney cells, but higher than the level 
observed in gills. This is consistent with the high levels of PPARα mRNA in liver and kidney, 
and PPARγ mRNA in adipose tissues in adult rodents (Lemberger, Braissant et al. 1996).  
 
5.2.2 Comparative levels of PPAR in tissues and cell lines 
Comparing levels of PPAR mRNA in muscle tissues, ASK and SHK-1 cell lines to liver 
tissues, revealed that PPARα expression was higher in muscle and cell lines than inn liver. 
This corresponds to data available in humans were PPARa is well expressed in kidney and 
muscle amongst other organs (Mukherjee, Jow et al. 1997). Regardless of the species, the 
expression of PPARα correlates with high mitochondrial and peroxisomal β-oxidation 
activities, as seen by its high levels in cells of the kidney proximal tubules, which primarily 
use fatty acids as an energy source. The PPARγ long and short were as expected significant 
lower in muscle tissue, ASK- and SHK-1 cell lines compared to liver. In adult rodents this is 
also the case, PPARγ has a restricted pattern of expression with adipose tissues being the 
major site  (Tontonoz, Hu et al. 1994). 
 
5.2.3 PPAR agonists 
The concentrations of ligand supplied to culture cells in this thesis were twice as high as 
standard levels used in similar studies with mammalian cell lines (Saidi, Holland et al. 2006).  
The concentration was increased because fish cells grown at  lower temperature (20°C) have a 
metabolism that are reduced compared to mammals, and an  increase in concentration is often 
necessary to induce activity. All ligands were added in same concentration for the sake of 
comparison. One of the challenges in treating cells with ligand solutions is to avoid 
cytotoxity. Whether the toxicity is time- or dose dependent must be taken into consideration 
when utilizing these ligands in the investigation of transcriptional regulation in cells.  
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5.2.4 Effect of PPAR agonists on cell morphology 
To investigate whether PPAR agonists had an effect on cells morphology, SHK-1 and ASK 
cells were cultured and supplemented with PPAR agonist in order to observe changes in a 
microscope. Neither SHK-1 and ASK cells seemed to change compared to control cells, when 
treated with fenofibrate for 24, 72 and 120 hours. ASK cells were not affected by treatment 
with rosiglitazone, whereas SHK-1 showed a significant change in morphology. The 
mechanism behind this is unknown. Treatment with TTA seemed to have a toxic effect on 
both cell lines. It has been hypothesized that TTA metabolites in Atlantic salmon  accumulate 
in the kidney, which results in poor growth, inhibition of inflammatory mediator production 
and thereby increasing mortality (Kleveland, Ruyter et al. 2006). The mechanism behind the 
findings of Kleveland et al. (2006) may be relevant to the observations of TTA induced 
toxicity in this present study.  
 
5.2.5 Fenofibrate- a PPARα agonist 
Fibrates have been used as cholesterol-lowering drugs for many years. Treatment with these 
agents results in a marked reduction in triglyceride-rich lipoprotein concentrations, a 
moderate decrease in LDL cholesterol and an increase in HDL cholesterol (Staels, 
Dallongeville et al. 1998). When 100 µM fenofibrate was supplied to SHK-1 cells, no 
significant up- or down regulation of either PPAR isotypes or their target genes were 
observed. The morphology experiment as described earlier, did not show any change in 
conformation. Although when looking at the results from viability test of both ASK and SHK-
1 cell lines, fenofibrate seems to have a toxic effect on the cells at this concentration, this is in 
agreement with studies on endometrial cancer cells where doses above 50 µM induces 
apoptosis (Saidi, Holland et al. 2006). 
 
5.2.6 Rosiglitazone- a PPARγ agonist 
The present qRT-PCR data show that PPARγ-agonist, rosiglitazone, a thiazolidinedione, 
stimulates SR-BI and CD 36 expression in SHK-1 cells. These observations are in agreement 
with the fact that both genes are under the positive control of PPARγ which itself is up-
regulated by oxidized LDL (von Schacky, Kiefl et al. 1993). Although viability tests showed 
no significant increase in cell death, rosiglitazone seemed to have a potent effect on SHK-1 
cell morphology. In the study by Saidi et al. (2006), it was reported that fenofibrate inhibits 
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cell proliferation in cancer cells, but the same effect was not seen with high doses of 
rosiglitazone. This correlates well with our findings.  
 
5.2.7 Expressing PPARγ splicing variants in Atlantic salmon cells 
To further investigate the effect of PPARγ in SHK-1, we transfected two PPARγ plasmid 
variants into SHK-1 cells, H15 (normal variant) and H16 (the short splicing variant missing 
34 aa of A/B domain). Cells transfected with H15 gave a significant up-regulation of PPARγ 
wt variant, and cells transfected with H16 gave a significant up-regulation of PPAR short 
splicing variant compared to nontransfected cells. Low transfection efficiency (2 %) raise 
questions about the validity of these results. Although it is unlikely that such low transfection 
efficiency would lead to the observed up-regulation, a possible explanation could be a self up-
regulation by internal activation as a response to increased PPARγ levels. 
 
Applying specific primers on samples transfected with PPARγ, shows up-regulation in SR-BI 
and CD 36, this is in agreement with PPARγ properties and our earlier findings. It is well 
established that lipid components of modified LDL activates PPARγ and thereby induced 
scavenger receptor CD 36 expression in macrophages (Nagy, Tontonoz et al. 1998) 
 
Transfected cells were immunofluoresecence stained in order to detect PPARγ expression. All 
the samples displayed green fluorescence signal throughout the whole cell. No specific green 
fluorescence stain could be attributed to PPARγ. Due to the low transfection efficiency (< 
2%), it is reasonable to assume that the chosen method and cell line were not optimal for this 
kinds of study. The low expression of PPARγ in SHK-1 cells and ASK, and the low 
transfection ratio makes it apparent that a more optimalized procedure is necessary in order 
study PPARγ expression and activation in Atlantic salmon cells. 
 
5.2.8 Detection of PPARγ relocation 
Cells were analyzed for relocation of PPARγ after treatment with rosiglitazone and applying 
immunofluorescence staining with anti-PPARγ antibody. No apparent relocation was 
observed in either sample. Green fluorescence signal was present throughout the cells, both in 
the nucleus and the cytosol. This was also the case for cells transfected with PPARγ plasmids, 
as discussed earlier. This could indicate either non-specific staining of primary antibody or 
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staining against endogenous PPAR. If the latter is the case, then  there should not be any 
reason primary antibody do not stain transfected PPARγ, but as transfected cells are few, it is 
likely that these cells are hard to detect.  
 
5.2.9 Protein detection  
To be able to study transfected PPARγ on the protein level, we performed western blotting 
with an antiserum against the receptor. The antiserum did not seem to function in 
immunoblots against the cloned PPARγ construct, but against endogenous PPARγ or 
moreover non-specific. Proteins of approximately 50 and 60 kDa were identified (the 
molecular weight of PPARs corresponds to around 50 kDa). There was no increase in 
expression signal in transfected cells. All cell samples, including control and pmaxGFPTM, 
expressed these signals. This strengthens the assumptions that the antiserum binds to 
endogenous PPARγ (correspond to band at 50 kDa) or that antiserum peptid was not PPARγ 
specific (band at 60 kDa).  
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CONCLUSION 
 
• Our findings of the PPAR activity in Atlantic salmon head kidney cells agrees in many 
aspects with previous findings in mammalian cells. 
 
• PPARs are expressed in higher levels in liver tissue than muscle and gills tisues and 
head kidney cell lines. 
 
• Specific PPAR agonists could have a toxic effect on SHK-1 and ASK cells in the 
concentration 100µM. 
 
• It was difficult to obtain high transfection efficiency in SHK-1 and ASK cells, it is 
necessary to optimalized the procedure and achieve higher tranfection efficiency to 
further study PPAR. 
 
• SHK-1 and ASK cells are not suitable models for PPAR studies, because of the low 
expression levels and low transfection efficiency. 
 
• Due to the low expression level and low transfection efficiency, it was not possible to 
determine the novel anti-PPARγ antibody level of specificity, with the head kidney 
salmon cells applied in this study.    
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